Powered by
Tags
Clinical Trial Management & support services

Overview

The full-service Contract Research Organization (CRO) with operations in Australia, New Zealand, Asia, North America, and Europe.

We specialize in delivering world-class operations, providing biotechs with strategic guidance from their early pre-clinical development with our experienced ClinicReady team through to late-phase studies, supported by our proven GlobalReady team. Our focus is on fast, agile, and adaptive operations that are solution-oriented, innovative, and cost-effective, ensuring rapid results and robust data.

With a proven track record and experience spanning across more than 120+ indications, Avance Clinical consistently delivers high-quality data that is accepted by global regulators, including but not limited to the TGA, FDA, MHRA, EMA, MFDS, PDMA.

Avance Clinical distinguishes itself by its commitment to personalized service rather than a one-size-fits-all approach.

EARLY PHASE SUCCESS
From comprehensive pre-clinical consultancy services through to phase one trials, we offer fast, agile and adaptive clinical research solutions for biotechs in the early phases of their drug development. The ClinicReady team, our inhouse scientific and regulatory affairs experts, lay the vital clinical foundations that ensure seamless and successful transition into phase one and beyond.

LATE PHASE SUCCESS
Our late phase operations deliver multi-regional clinical excellence across key therapeutic areas including oncology, CNS, rare diseases and infectious diseases. Our global teams apply decades of drug development experience, and leverage the latest technology, including AI and gold standard systems and processes, across all functional areas to deliver an exceptional CRO experience for biotechs.

Delegates

Yvonne
Yvonne Lungershausen
Chief Executive Officer
Madison
Madison Esely-Kohlman
Director of Business Development
John-Mann-1-Pic-210
John R. Mann
Executive Vice President, North American Operations

Resources

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia. This trial aims to evaluate Oragenics’ lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion. ONP-002, a novel chemical entity (NCE), is delivered through a unique intranasal device and designed to maximize drug delivery directly to the brain.
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS, cardiometabolic, and rare diseases specialist CRO with extensive site relationships in the region.